ページの先頭です
HOME > Past Issue List > Issue List > Abstract
言語を選択(Language)
日本語(Japanese)English

Abstract

Vol.65 No.3 May 2017

A phase III study of sequential intravenous/oral levofloxacin in adult patients with acute bacterial prostatitis or acute epididymitis

Ryoichi Hamasuna1), Mitsuru Yasuda2), Shingo Yamamoto3), Kenji Ito4), Kazuya Kawahara5), Motoshi Kawahara6), Shin Ito7), Shoji Hara8), Shinichi Minamitani9), Yasuyuki Okuda9) and Tetsuro Matsumoto10)

1)Department of Urology, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan
2)Department of Urology, Gifu University Hospital
3)Department of Urology, Hyogo College of Medicine
4)Ito Urology Clinic
5)Kawahara Nephro-Urological Clinic
6)Kawahara Urology Clinic
7)iClinic
8)Hara Genitourinary Hospital
9)R&D Division, Daiichi Sankyo Co., Ltd.
10)Professor emeritus, University of Occupational and Environmental Health, Japan

Abstract

Purpose: This study was a multicenter phase III study to evaluate the efficacy and safety of sequential intravenous/oral levofloxacin (LVFX) 500 mg to patients with acute bacterial prostatitis or acute epididymitis.
Material and methods: The subjects were patients with acute bacterial prostatitis or acute epididymitis and were administered LVFX 500 mg by intravenous injection once a day for 3 to 7 days, followed by oral LVFX 500 mg once a day for 11 to 14 days. The efficacy of the levofloxacin regimen was evaluated according to the Japanese Guideline for Clinical Research of Antimicrobial Agents on Urogenital Infections (the first edition).
The primary endpoint of microbiological efficacy was the microbial eradication rate at 5 to 9 days after the completion of the oral LVFX treatment period.
Results: The microbiological eradication rate was 83.3% (5/6) in the patients with acute bacterial prostatitis, and 83.3% (5/6) in the patients with acute epididymitis. The clinical efficacy rate at 5 to 9 days after completion of the oral LVFX treatment period was 83.3% (5/6) in the patients with acute bacterial prostatitis, and 66.7% (4/6) in the patients with acute epididymitis. The incidence rates of adverse events and adverse drug reactions (ADRs) were 38.9% (7/18) and 22.2% (4/18), respectively. The ADRs were mild and recovered without special treatments.
Conclusion: The sequential intravenous/oral therapy with LVFX 500 mg once a day is effective and safe against acute bacterial prostatitis and acute epididymitis.

Key word

levofloxacin, acute bacterial prostatitis, acute epididymitis

Received

October 18, 2016

Accepted

January 12, 2017

Jpn. J. Chemother. 65 (3): 484-490, 2017